NuProbe is a company developing technologies in genomics for disease detection. It develops a PCR-based (polymerase chain reaction) enrichment method called blocker displacement amplification for selective amplification of low abundant sequence variants in a background of wildtype DNA.
Type | Private | |
Founded | 2016 | |
HQ | Cambridge, MA, US | Map |
Website | nuprobe.com | |
Employee Ratings |
Employees (est.) (Aug 2022) | 73 | (+2%) |
Cybersecurity rating | A | More |
Founding Date | 2016 |
NuProbe total Funding | $53 m |
NuProbe latest funding size | $42 m |
Time since last funding | 2 years ago |
NuProbe investors | WuXi AppTec, Yonghua Capital, Sequoia Capital China, BioTrack Capital, Serica Partners, Taifu Capital, Panlin Capital, Juming Capital, Tuobang Capital, Ruomu Capital |
NuProbe has 101 Twitter Followers. The number of followers has increased 1.4% month over month and increased 4.8% quarter over quarter
174
Tweets
128
Following
101
Followers
1
Tweets last 30 days
3
Avg. likes per Tweet
100%
Tweets with engagement
When was NuProbe founded?
NuProbe was founded in 2016.
Who are NuProbe key executives?
NuProbe's key executives are Yingshuang Chai, Nicolas Garreau de Loubresse and Yundi Chen.
How many employees does NuProbe have?
NuProbe has 73 employees.
Who are NuProbe competitors?
Competitors of NuProbe include Serimmune, Sirigen and Rapture Biotech.
Where is NuProbe headquarters?
NuProbe headquarters is located at 85 Bolton St, Cambridge.
Where are NuProbe offices?
NuProbe has offices in Cambridge and Houston.
How many offices does NuProbe have?
NuProbe has 4 offices.
Receive alerts for 300+ data fields across thousands of companies